ERBB2 and carcinoma: Consistent with previous reports, HER2-positivity was more frequent with well- or moderately differentiated histology (50% and 26%, respectively) (Shan et al., 2013; Son et al., 2014; Rajagopal et at., 2015), compared with poorly differentiated carcinomas (23%).